LB PHARMACEUTICALS INC
LBRXHeld by 4 specialist biotech funds
High Convergence4 funds opened new positions. Next phase3 readout (LB-102 (50 mg tablet)): Jun 2027. Short interest: 13.1% of float.
Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.